Puma Biotechnology | PBYI - Loan Capital


Puma Biotechnology reported $10.87M in Loan Capital for its fiscal quarter ending in June of 2025.





Loan Capital Change Date
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
Amgen USD 50B 2.43B Dec/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Daiichi Sankyo JPY 300.15B 199.41B Dec/2025
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Glaxosmithkline GBP 19.82B 203.13M Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
MacroGenics USD 70M 256K Dec/2025
Moderna USD 610M 584M Dec/2025
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 57.41B 93M Sep/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Takeda JPY 4.27T 81.29B Dec/2025
TG Therapeutics USD 245.64M 305K Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025